Delegation of China Association for the promotion of drugs to attend "2017 Asia Pacific biotechnology Investment Forum"

Source: China pharmaceutical innovation promotion association 2017-12-08 December 6, 2017, "2017 Asia Pacific biotechnology Investment Forum" (2017 Asia Pacific biotechnology Investment Forum), sponsored by diamond biotechnology Investment Co., Ltd (hereinafter referred to as "Diamond biotechnology investment"), was held in Taipei As the support unit of this meeting, China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") organized 14 representatives from more than 10 enterprises to attend the forum At the meeting, important guests from international well-known investment banks J.P Morgan, Fubon Financial Holding, China Development Fund, Shanghai Institute of pharmaceutical research of Chinese Academy of Sciences, Hong Kong Federation of biotechnology, and food and Drug Administration of Taiwan Ministry of health and welfare gathered together More than 30 top biotechnology and pharmaceutical enterprises and more than 400 representatives attended the forum At the beginning of the conference, Chen Shizhong, head of Taiwan's health and welfare authority, Zheng zhenmao, head of financial supervision and regulation authority, and Qian Guowei, vice president of Asia Pacific and President of Taiwan, delivered opening speeches respectively John Whittaker, managing director of global health from J.P Morgan, and Wu Jun, CO managing director of Asia Pacific healthcare investment banking, analyzed the trends of global biotechnology capital market and Asia Pacific biotechnology industry in detail Li Zude, vice chairman of diamond biotechnology investment, Su Fangqing, under secretary of government of the Ministry of science and technology, Zhang Zhenshan, deputy director of the securities and Futures Bureau and other representatives expressed their opinions, and held a heated discussion on "investment opportunities for biotechnology industry in Taiwan" Song Ruilin, executive chairman of the China Association for the promotion of drugs, made a wonderful keynote report in combination with the opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical and medical devices recently issued by the general office of the CPC Central Committee and the general office of the State Council President song also mentioned that the 2017 China Pharmaceutical Innovation and Innovation Conference held by the China Council for the promotion of drugs in Suzhou at the end of October this year attracted 1318 relevant enterprises, including 351 pharmaceutical enterprises, 96 medical device enterprises, 442 investment institutions, more than 400 other institutions and more than 2000 representatives The scale of the conference was unprecedented The 2018 conference will be held in Suzhou from September 18 to 20 You are welcome to attend at that time After the keynote speech by President song Ruilin, representatives of the pharmaceutical industry and academia from the three regions on both sides of the Taiwan Straits discussed "the development trend and cooperation opportunities of biotechnology in the three regions on both sides of the Taiwan Straits" At the same time, representatives of pharmaceutical innovative enterprises from both sides of the Taiwan Strait were invited to give a roadshow report As an international leader in the field of apoptosis and autophagy dual channel regulation of small molecule drug research and development, Yang Dajun, chairman of Yasheng pharmaceutical, introduced the company's achievements in the design and development of new target original new drugs, the research of translational medicine and the development of preparations He also mentioned that the company is actively preparing to go public in the United States Li Ying, director of strategic cooperation of Beida pharmaceutical, Li Yingxin, senior international BD Manager of LVYE Pharmaceutical Group and Lin Nanhong, executive deputy general manager of Tangji biomedical also shared their latest achievements in the field of R & D, attracting the attention of many venture capital and capital markets This forum brought together representatives from the pharmaceutical industry and investment community of both sides of the Taiwan Strait, and successfully facilitated the negotiation and cooperation between many enterprises, investors and biotechnology companies It laid a good foundation for promoting the communication and cooperation between the pharmaceutical industries of both sides of the Taiwan Strait, which is conducive to giving full play to their respective resource advantages, learning from each other's strengths and complementing each other's weaknesses, and jointly improving the overall level and industrial capacity of Chinese pharmaceutical innovation Representatives from Nanjing Shenghe Pharmaceutical Co., Ltd., Yiming Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Co., Ltd., Shanghai Gonghe Vacuum Technology Co., Ltd., Haoding biomedical technology (Shanghai) Co., Ltd., aimeida (Beijing) Pharmaceutical Information Consulting Co., Ltd and other mainland enterprises participated in the above activities.